Biocon banks on new biosimilar launches, insulin franchise to drive stronger H2 FY27

What happened

Biocon expects a significantly stronger second half of FY27, supported by recent biosimilar launches, insulin demand and a gradual recovery at Syngene International. In the September quarter, net profit fell 52% year on year to Rs 41 crore, while revenue rose 2% to Rs 4,389 crore; delayed biosimilar shipments shifted revenue recognition into October.

Confirmed

Global impact / market context

The delayed shipments moved revenue between quarters rather than eliminating it, but the reported profit decline also reflects higher depreciation, lower other income and continued investment in growth platforms. A stronger second half depends on launches, insulin sales and Syngene’s recovery delivering enough revenue to offset those pressures.

Analyst inference

Biocon’s quarter shows how shipment timing can make results uneven: around $20 million of biosimilar revenue was not recognised by September and was booked in October. Investors will weigh that timing effect against the 7% EBITDA decline, a measure of operating earnings before interest, tax, depreciation and amortisation.

Analyst inference

What to watch

1. Check whether biosimilar sales and revenue recognition remain steady after the October booking, since further shipment delays could shift reported revenue between quarters again. Analyst inference
2. Track insulin demand and recently launched biosimilars in the second half; Biocon identifies both as drivers of its expectation for stronger performance. Confirmed
3. Watch for evidence that Syngene International’s gradual recovery offsets the weak September quarter, while higher depreciation and continued growth investment remain pressures on profit. Analyst inference

Evidence

• Original source link unavailable